Search results
- Lupin is the 6th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).
People also ask
Is Lupin the fastest growing pharmaceutical company in the US?
Is Lupin a Japanese company?
Who owns Lupin Pharmaceuticals?
What is the market capitalization of Lupin?
Generic Health, Lupin’s subsidiary in Australia, is among the fastest growing pharmaceutical companies in the country. It is a leading provider of high-quality generic prescription, injectable and over-the-counter medicines, supplying to pharmacies and hospitals across Australia.
- About Lupin Limited
- Lupin Limited - Industry Details
- Lupin Limited - Startup Story
- Lupin Limited - Mission and Vision
- Lupin Limited - Name, Tagline, Logo
- Lupin Limited - Business Model
- Lupin Limited - Revenue Model
- Lupin Limited - Funding and Investors
- Lupin Limited - Mergers and Acquisitions
- Lupin Limited - Advertisements and Social Media Campaigns
Founded in 1968, Lupin Limited is an Indian global pharmaceutical corporation headquartered in Mumbai, Maharashtra. It offers Branded and Generic Formulations, Biosimilars, and Active Pharmaceutical Ingredients (APIs). It is one of the world's largest generic pharmaceutical firms in terms of revenue. Presently, Lupin is the 6th Largest Indian Pharm...
The constant improvement in the areas of medicines and drugs with huge technological advancements has significantly impacted this space of the pharma industry. Due to this progress, it is anticipated that the pharma industrywill see growth at a compound annual growth rate (CAGR) of 11.34% from 2021 to 2028.
In 1968, Lupin commenced its first business. Desh Bandhu Gupta borrowed Rs 5000 from his wife to establish Lupin. In the initial days, the company had only two employees; a peon and a typist. Gradually, the firm was able to launch its production plant for making folic acid and iron tablets for the Government of India's mother and child health progr...
The mission statement of Lupin is, "To become a transnational pharmaceutical company through the development and introduction of a wide portfolio of branded and generic products in key markets." The company aims to consistently produce high-quality and innovative products that are solely focused to improve the healthcare sector. The core values tha...
Desh Bandhu Gupta was inspired by the 'Lupin flower' for which he named the company after it. The Lupin flower is said that it can grow even in harsh conditions and can also nourish the soil at the same time. The flower's ability of unselfish giving and resiliency is what roused Desh Bandhu Gupta to provide quality medical needs to people. The tagl...
The business operations of Lupin cover the whole pharmaceutical value chain, from biotechnology to branded and generic formulations, APIs, biosimilars, specialty drugs, therapeutic areas, and cutting-edge drug delivery technologies. It has produced over 10,000 products till now. With the creation of medications for the treatment of multi-drug resis...
As of FY22, the total revenue of Lupin stood at $2.2 billion. Lupin generates its maximum revenue from India around 38% of revenue, from North America - 36%, Growth Markets (Australia, Brazil, and Mexico)- 9%, EMEA (South Africa and EU)- 9%, and the Rest of the World - 2%. It is also reported that it renders 6% of its revenue through APIs and anti-...
Baring Private Equity India provided funds to Lupin in Post-IPO Equity round on September 1, 2013. However, the details of the total funds raised by Lupin are undisclosed.
Till now, Lupin has purchased nine different businesses. Southern Cross Pharma, a privately held corporation that supplies pharmaceutical items to the Australian and New Zealand markets, was their most recent purchase as of July 30, 2021.
In 2022, Lupin came up with the campaign #BanoKhudSeBehetar to promote its 100% Ayurvedic Energy and Immunity capsules. The ad features Bollywood actor, Hrithik Roshan. Here's what Anil Kaushal, Head of OTC Business, Lupin, said about the campaign, "In today’s highly demanding times, a product like ‘Be One’ is only increasing in relevance. The cons...
- 1968
- 15299.25 Crores- (FY2020-21)
- Desh Bandhu Gupta
- Private
Lupin is the fastest-growing Top 10 generic pharmaceuticals player in Japan (IMS) [citation needed]. It operates in Japan through its subsidiary, Kyowa Pharmaceutical Industry Co. Ltd. (Kyowa), a company acquired in 2007, [28] [29] and I’rom, Pharmaceutical Co. Ltd (IP), acquired in 2011.
Sep 10, 2024 · Lupin is the 6th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).
- 21K
- 3rd Floor, Kalpataru Inspire, Off. Western Expressway Highway, Santacruz (East), Mumbai, India
Focus on High-valueSpecialty Generics. Specialty drugs used to treat rare and chronic diseases such as cancer and multiple sclerosis are driving the demand for more affordable generic versions. This segment is expected to grow at a 12.1% CAGR (Source: KPMG Report) through 2024.
Lupin entered the U.S. generic pharmaceutical market in 2003 with ANDA approval for Cefuroxime Axetil Tablets. We have since received more than 250 FDA approvals and market a total of 180 generic products. This has solidified us as one of the fastest-growing pharmaceutical companies in the U.S.
In 2014, it set up a venture with Yoshindo, a generic drug company based in Japan's Toyama Prefecture, to jointly develop generic biomedicines.
